LAMELLASOME formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been successfully used for the in vivo delivery of functional nucleic acids to lung cells in animal models (For more information, please see our Evidence base).
Lamellar is developing its own pipeline of nucleic acid-based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
LAMELLASOME™ CF-NA is a LAMELLASOME™/plasmid DNA treatment targeted at functional CFTR (Cystic fibrosis transmembrane conductance regulator) replacement therapy for Cystic Fibrosis. Lamellar has data to prove that LAMELLASOME™ CF-NA provides safe and effective delivery of functional plasmid to lungs in vivo, while avoiding gene therapy-associated immune response.
LAMELLASOME™ IPF-NA is a LAMELLASOME™/microRNA product that is being developed for the treatment of idiopathic pulmonary fibrosis.